PROGRAM CHAIR
Justine V. Cohen, DO
Dana-Farber Cancer Institute
Melanoma Oncology
Boston, MA
PROGRAM OVERVIEW
This educational Whiteboard Snapshot online enduring program focuses on the latest updates in novel-targeted and immunotherapeutic approaches for melanoma, including identifying targetable mutations and determining eligibility for immunotherapy. Additional considerations regarding pearls for adverse event recognition and management, as well as leveraging shared decision making and the multidisciplinary team are included as part of a comprehensive approach to care in melanoma.
TARGET AUDIENCE
This program will reach the medical oncology team, including dermatologic oncologists, general oncologists, and multidisciplinary healthcare professionals working collaboratively to provide the best possible care for patients with melanoma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement best practices for assessment of targetable mutations and eligibility for immuno-therapeutic treatment of melanoma
- Examine the latest updates in novel-targeted and immuno-therapeutic treatment approaches
- Identify potential unique adverse events associated with novel therapeutics and implement patient-centric education, monitoring and reporting protocols
- Integrate best practices for patient education and communication, including strategies for discussing treatment options, concerns and monitoring for/managing adverse events
- Establish best practices for peer-to-peer expert communication for optimal multidisciplinary care of patients with melanoma
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosure |
| Justine Cohen, MD | Dr. Cohen reports she received consultant fees from Advisory Boards for BMS, Replimune, and Incyte. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 12, 2023
EXPIRATION DATE: December 12, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Emily S. Ruiz, MD, MPH
Associate Professor of Dermatology, Harvard Medical School
Director, High-Risk Skin Cancer Clinic, Dana-Farber Cancer Institute
Program Director, Micrographic Surgery and Dermatology Oncology Fellowship, Brigham and Women’s Hospital
Boston, MA
PROGRAM OVERVIEW
This educational Whiteboard Snapshot online enduring program focuses on the latest updates in novel-targeted and immunotherapeutic approaches for basal cell carcinoma and cutaneous squamous cell carcinoma, including identifying targetable mutations and determining eligibility for immunotherapy. Additional considerations regarding pearls for adverse event recognition and management, as well as leveraging shared decision making and the multidisciplinary team are included as part of a comprehensive approach to care in non-melanoma skin cancers.
TARGET AUDIENCE
This program will reach the medical oncology team, including dermatologic oncologists, general oncologists, and multidisciplinary healthcare professionals working collaboratively to provide the best possible care for patients with cutaneous malignancies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement best practices for assessment of targetable mutations and eligibility for immuno-therapeutic treatment of non-melanoma skin cancers (NMSCs)
- Examine the latest updates in novel-targeted and immuno-therapeutic treatment approaches
- Identify potential unique adverse events associated with novel therapeutics and implement patient-centric education, monitoring and reporting protocols
- Integrate best practices for patient education and communication, including strategies for discussing treatment options, concerns and monitoring for/managing adverse events
- Establish best practices for peer-to-peer expert communication for optimal multidisciplinary care of patients with NMSCs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosure |
| Emily S. Ruiz, MD, MPH | Dr. Ruiz reports that she is a consultant for Checkpoint Therapeutics, Regeneron Pharmaceuticals, and Feldman Pharmaceuticals. She also serves as a principal investigator/co-investigator for Regeneron and a co-investigator for Merck and Castle Biosciences. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 12, 2023
EXPIRATION DATE: December 12, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
